These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9668299)

  • 21. 'Seronegative' myasthenia gravis is no longer seronegative.
    Lindstrom J
    Brain; 2008 Jul; 131(Pt 7):1684-5. PubMed ID: 18558616
    [No Abstract]   [Full Text] [Related]  

  • 22. Acetylcholine receptor antibody production by bone marrow cells in a patient with myasthenia gravis.
    Fujii Y; Monden Y; Hashimoto J; Nakahara K; Kawashima Y
    Neurology; 1985 Apr; 35(4):577-9. PubMed ID: 3982648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis.
    Poëa-Guyon S; Christadoss P; Le Panse R; Guyon T; De Baets M; Wakkach A; Bidault J; Tzartos S; Berrih-Aknin S
    J Immunol; 2005 May; 174(10):5941-9. PubMed ID: 15879086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agrin-induced aggregation of acetylcholine receptors in muscles of rats with experimental autoimmune myasthenia gravis.
    Rimer M
    Ann N Y Acad Sci; 1998 May; 841():546-9. PubMed ID: 9668292
    [No Abstract]   [Full Text] [Related]  

  • 25. Myasthenia gravis associated with etanercept therapy.
    Fee DB; Kasarskis EJ
    Muscle Nerve; 2009 Jun; 39(6):866-70. PubMed ID: 19373885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility of HLA DR3 transgenic mice to experimental autoimmune myasthenia gravis.
    Raju R; Zhan WZ; Karachunski P; Sieck GC; Conti-Fine BM; David CS
    Ann N Y Acad Sci; 1998 May; 841():360-4. PubMed ID: 9668259
    [No Abstract]   [Full Text] [Related]  

  • 27. Antiidiotypic antibodies in the regulation of experimental autoimmune myasthenia gravis.
    Souroujon MC; Fuchs S
    Ann N Y Acad Sci; 1987; 505():676-82. PubMed ID: 3500670
    [No Abstract]   [Full Text] [Related]  

  • 28. Clonotypic analysis of anti-acetylcholine receptor antibodies from experimental autoimmune myasthenia gravis-sensitive Lewis rats and experimental autoimmune myasthenia gravis-resistant Wistar Furth rats.
    Zoda T; Yeh TM; Krolick KA
    J Immunol; 1991 Jan; 146(2):663-70. PubMed ID: 1987281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis.
    Cufi P; Dragin N; Weiss JM; Martinez-Martinez P; De Baets MH; Roussin R; Fadel E; Berrih-Aknin S; Le Panse R
    Ann Neurol; 2013 Feb; 73(2):281-93. PubMed ID: 23280437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leukoplasmapheresis for myasthenia gravis. Acetylcholine receptor antibody production.
    Seybold ME; Tsoukas C; Lindstrom J; Fong S; Vaughan J
    Arch Neurol; 1982 Jul; 39(7):433-5. PubMed ID: 6980639
    [No Abstract]   [Full Text] [Related]  

  • 31. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody.
    Tüzün E; Li J; Saini SS; Yang H; Christadoss P
    J Neuroimmunol; 2007 Jan; 182(1-2):167-76. PubMed ID: 17137637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epitope analysis of AChR Ab in patients with myasthenia gravis using sensitive enzyme immunoassay.
    Hayashi M; Kohno T; Yoshinaga J; Kida K
    Ann N Y Acad Sci; 1998 May; 841():478-81. PubMed ID: 9668279
    [No Abstract]   [Full Text] [Related]  

  • 33. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.
    Plomp JJ; Huijbers MG; van der Maarel SM; Verschuuren JJ
    Ann N Y Acad Sci; 2012 Dec; 1275():114-22. PubMed ID: 23278586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Myasthenia gravis (1). Experimental myasthenia gravis--a tool for the study of the pathogenesis, diagnosis and treatment of myasthenia gravis].
    Heilbronn E
    Lakartidningen; 1978 Oct; 75(41):3663-4, 3669. PubMed ID: 692231
    [No Abstract]   [Full Text] [Related]  

  • 35. 'Split tolerance' induction by intrathymic injection of acetylcholine receptor in a rat model of autoimmune myasthenia gravis; implications for the design of specific immunotherapies.
    Ohtsuru I; Matsuo H; Fukudome T; Suenaga A; Tsujihata M; Nagataki S
    Clin Exp Immunol; 1995 Dec; 102(3):462-7. PubMed ID: 8536358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-idiotypic antibodies in the study and treatment of experimental autoimmune myasthenia gravis.
    Souroujon MC; Fuchs S
    Methods Enzymol; 1989; 178():433-48. PubMed ID: 2601627
    [No Abstract]   [Full Text] [Related]  

  • 37. Lymphocyte activation in experimental autoimmune myasthenia gravis.
    De Baets MH; Einarson B; Lindstrom JM; Weigle WO
    J Immunol; 1982 May; 128(5):2228-35. PubMed ID: 6977589
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical heterogeneity of seronegative myasthenia gravis.
    Evoli A; Batocchi AP; Lo Monaco M; Servidei S; Padua L; Majolini L; Tonali P
    Neuromuscul Disord; 1996 May; 6(3):155-61. PubMed ID: 8784802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis.
    Ostlie NS; Karachunski PI; Wang W; Monfardini C; Kronenberg M; Conti-Fine BM
    J Immunol; 2001 Apr; 166(8):4853-62. PubMed ID: 11290761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunopathology of myasthenia gravis.
    Drachman DB
    Fed Proc; 1979 Nov; 38(12):2613-5. PubMed ID: 227751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.